1) Prelude:
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. It was founded in September 2010.
The company’s name is derived from the terms “modified RNA” and “moderna”.
2) Usage:
The company’s commercial products are the Moderna COVID-19 vaccine, sold under the brand name Spikevax and mNexspike, a respiratory syncytial virus vaccine sold under the brand name mRESVIA, an influenza vaccine sold under the brand name mFluvisa.
The company has 44 treatments and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein-Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine—funded by the Biomedical Advanced Research and Development Authority—and three cancer vaccines.
In 2026, Time ranked Moderna as number one in their world’s impactful companies list.
(III) Product development:
In 2013, the company formed a partnership with “AstraZeneca” to develop treatments for cardiovascular, metabolic and renal diseases as well as cancer. Moderna was also awarded a $25 million grant by “DARPA” through a program for Autonomous Diagnostics to enable prevention and therapeutics, prophylactic options to environmental and chemical threats (ADEPT-PROTECT). Its goal was to develop an mRNA vaccine with the capability to suppress a global pandemic within 60 days.
In August 2025, “mFluvisa”, an “mRNA” vaccine against influenza, intended for individuals aged 50 years of age and older was approved for medical use in the United States.
(IV) “COVID-19 Vaccine”
From 2020 to 2021, Moderna received $4.9 billion from Operation Warp Speed to accelerate development of its COVID-19 vaccine with $1.9 billion committed in total for producing 300 million vaccine doses.
In March 2020, the USA Food and Drug Administration (FDA) approved clinical trials for the Moderna COVID-19 vaccine candidates.
(V) MODERNA’s Financial Data:
These are some revenue data of financials about the company. They are:—
| Year | Net Income US$ | Revenue – US$ |
|---|---|---|
| 2025 | 2890 | 1950 |
| 2024 | 3650 | 3200 |
| 2023 | 4710 | 6848 |
| 2022 | 8362 | 19263 |
| 2021 | 12202 | 19441 |
(VI) Opportunity for investors:
Moderna offers a mix of opportunity and uncertainty for the investor looking for investments in pharma. The company has a strong scientific platform, growing pipeline of vaccines and therapies and recent positive clinical data. It faces questions about long-term profitability, competition and execution risks.
Strengths of Moderna as an investment:
There are a lot of reasons and are a lot of reasons to invest in the company like:—
(A) Proven MRNA platform
(B) Diversifying product portfolio
(C) Strong clinical pipeline
(D) Dozens of programs
(E) Strategic partnerships
(F) Solid cash position
More The Reads: NVIDIA (NVDA) Common Stock Performance and Investors Analysis
Conclusion:
Moderna, Inc. is more than just a COVID-19 vaccine company. It is building a broad portfolio of mRNA-based vaccines and therapies across respiratory diseases, cancer and rare disorders.
If you want clean, ongoing analysis of “mRNA Moderna” and other high-potential biotech stocks, subscribe to our newsletter for regular insights and timely updates. The company reinvests its cash into research, development and pipeline expansion.
FAQ
Q1: Is Moderna stock expected to go up?
Ans: Moderna (Nasdaq) recently surged over 170% following historic Phase-3 clinical trial results for its mRNA skin cancer vaccine, partnered with Merck.
Q2: What are the three hottest stocks right now?
Ans: The hottest and most heavily discussed stocks during market momentum are NVIDIA, Meta Platforms and CBRS.
Q3: Why is Moderna being sued?
Ans: Moderna is facing several patent infringement lawsuits from rival drugmakers regarding the messenger RNA.
Disclaimer:
Financial disclaimers for Moderna, Inc. common stock (NASDAQ) “MRNA” states that stock quotes, research data, and estimates are for informational use only.
They do not constitute formal investment advice, personal recommendations or guarantees of future performance as biotech stocks carry high clinical, market and regulatory risks. The author does not take any responsibility about the investment in the company. The writer does not have any advice and risks of financial losses in the company.